Summary:
Dedicated to discovering and developing breakthrough cell-based therapies for metabolic disorders including primary hyperoxaluria, kidney stones, and other oxalate-related conditions, and insulin-dependent diabetes.
Visit Ixion Biotechnology.

Description (Web site quote):
Ixion is a Florida-based, clinical-stage biotechnology company that is developing therapies focused on treatment of metabolic disorders.

Ixion's two core business units are:

* Oxalate Control: therapies for Primary Hyperoxaluria (an "orphan" disease), recurrent kidney stones, and other oxalate-related conditions, based on our proprietary use of unique oxalate-degrading bacteria and

* Stem Cell / Diabetes: somatic cellular therapies to treat diabetes, based on selecting, proliferating, and directing the differentiation of adult pancreatic stem cells into insulin-producing islet preparations for transplantation.
Visit Ixion Biotechnology.